News from nordic nanovector A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Feb 18, 2021, 01:32 ET Nordic Nanovector ASA: Results for the Fourth Quarter and Full Year 2020

Nordic Nanovector ASA (OSE: NANOV) announces its results for the fourth quarter and full year 2020. A live webcast presentation by Nordic...

Feb 18, 2021, 01:07 ET Nordic Nanovector Sees Significant Improvement in Patient Recruitment Rate in PARADIGME, its Single-arm Phase 2 Pivotal Trial with Betalutin® in R/R Follicular Lymphoma

Nordic Nanovector ASA (OSE: NANOV) provides an update on PARADIGME, its ongoing pivotal Phase 2b trial of Betalutin® (177Lu lilotomab satetraxetan)...

Feb 15, 2021, 12:19 ET Nordic Nanovector ASA: Invitation to Fourth Quarter and Full Year 2020 Results Presentation and Webcast

Nordic Nanovector ASA (OSE: NANOV) announces that it will report its results for the fourth quarter and full year 2020 on Thursday, 18 February 2021. ...

Dec 21, 2020, 04:12 ET Nordic Nanovector - Financial Calendar 2021

Nordic Nanovector ASA (OSE: NANOV) provides an update for its Financial Calendar for 2021. 18 February 2021 - Quarterly Report - Q4'2020 / FY'2020 15 ...

Dec 07, 2020, 05:20 ET Nordic Nanovector to Present at DNB's 11th Annual Nordic Healthcare Conference

Nordic Nanovector ASA (OSE: NANOV) announces that its Interim CEO, Dr Lars Nieba will present a corporate overview via live webcast at DNB's 11th...

Dec 01, 2020, 01:42 ET Nordic Nanovector completes patient enrolment into Phase 1 trial of Betalutin® in Diffuse Large B Cell Lymphoma

Nordic Nanovector ASA (OSE: NANO) announces that it has completed enrolment into the LYMRIT 37-05 Phase 1 clinical trial of Betalutin® (177Lu...

Nov 30, 2020, 02:20 ET Nordic Nanovector announces change of its Oslo Børs ticker symbol to 'NANOV'

Nordic Nanovector ASA (OSE: NANOV) announces that the Company's ticker symbol on the Oslo Børs will change from 'NANO' to 'NANOV' and will be...

Nov 19, 2020, 01:42 ET Nordic Nanovector ASA: Results for the Third Quarter 2020

Nordic Nanovector ASA (OSE: NANO) announces its results for the third quarter 2020. A live webcast presentation by Nordic Nanovector's management...

Nov 19, 2020, 01:41 ET Nordic Nanovector completes enrolment into second safety cohort of follicular lymphoma patients in Archer-1 Phase 1b Betalutin®/rituximab combination trial

Nordic Nanovector ASA (OSE: NANO) announces that it enrolled the final two patients into the second safety cohort of its Phase 1 Archer-1 (LYMRIT...

Nov 16, 2020, 06:44 ET Nordic Nanovector to Present at Upcoming Jefferies Virtual London Healthcare Conference

Nordic Nanovector ASA (OSE: NANO) announces that its Interim CEO, Dr Lars Nieba will present a corporate overview, via live webcast, and host...

Nov 16, 2020, 02:22 ET Nordic Nanovector ASA: Invitation to Q3 2020 Results Presentation and Webcast

Nordic Nanovector ASA (OSE: NANO) announces that it will report its results for the third quarter 2020 on Thursday, 19 November 2020. A presentation...

Oct 21, 2020, 11:58 ET Nordic Nanovector ASA: Cancellation of Repair Offering

Reference is made to the stock exchange announcement by Nordic Nanovector ASA (the "Company") on 23 and 30 September 2020 where the Company announced ...

Oct 21, 2020, 05:48 ET Nordic Nanovector ASA: Extraordinary general meeting held

Nordic Nanovector ASA (the "Company") announces that an extraordinary general meeting ("EGM") in the Company was held today at the Company's offices...

Oct 19, 2020, 09:32 ET Nordic Nanovector ASA - Streaming details for EGM

Nordic Nanovector ASA (the "Company") will carry out an Extraordinary General Meeting (EGM) on 21 October 2020 at 10:00 CET. The EGM will be held at...

Oct 08, 2020, 02:22 ET Nordic Nanovector publishes results of preclinical study demonstrating Betalutin® reverses tumour resistance to rituximab in NHL disease models

Nordic Nanovector ASA (OSE: NANO) announces that its preclinical study investigating the ability of Betalutin® (177Lu-lilotomab satetraxetan) to...

Sep 03, 2020, 02:12 ET Nordic Nanovector - Mature Data from the LYMRIT 37-01 - Part A trial, Published in Blood Advances

Nordic Nanovector ASA (OSE: NANO) announces the publication in Blood Advances, an official journal of the American Society of Hematology, of the...

Sep 01, 2020, 10:31 ET Nordic Nanovector to Present at Upcoming Pareto Securities 11 th Healthcare Conference

Nordic Nanovector ASA (OSE: NANO) announces that its management team will present a corporate overview and host one-on-one meetings with investors at ...

Aug 27, 2020, 01:26 ET Nordic Nanovector ASA: Results for the Second Quarter and First Half 2020

Nordic Nanovector ASA (OSE: NANO) announces its results for the second quarter and first half 2020. A presentation by Nordic Nanovector's management...

Aug 21, 2020, 11:16 ET Nordic Nanovector ASA: Invitation to Second Quarter and First Half 2020 Results Presentation and Webcast - correction

Nordic Nanovector ASA (OSE: NANO) announces that it will report its results for the second quarter and first half 2020 on Thursday, 27 August 2020. A ...

Aug 21, 2020, 10:12 ET Nordic Nanovector ASA: Invitation to Second Quarter and First Half 2020 Results Presentation and Webcast

A presentation by the Nordic Nanovector's senior management team will take place the same day at 8:30 am CEST at: Thon Hotel Vika Atrium,...

Aug 10, 2020, 01:28 ET Nordic Nanovector Appoints Dr Christine Wilkinson Blanc as Chief Medical Officer

Nordic Nanovector ASA (OSE: NANO) announces that Dr Christine Wilkinson Blanc has been appointed Chief Medical Officer with immediate effect. Dr...

Aug 06, 2020, 01:12 ET Independent Review Committee Recommends Nordic Nanovector to focus on one dosage arm for the Pivotal PARADIGME Phase 2b Trial in Patients with 3L R/R FL

Nordic Nanovector ASA (OSE: NANO) today announces that, following a planned interim analysis of the PARADIGME Phase 2b pivotal trial of Betalutin® in ...

Jul 30, 2020, 02:22 ET Nordic Nanovector Announces EU Patent Granted Covering the Use of Alpha37

Nordic Nanovector ASA (OSE: NANO) is pleased to announce the grant of an EU patent covering the use of Alpha37 for the treatment of Chronic...

Jul 01, 2020, 10:37 ET Nordic Nanovector ASA - Share Capital Increase Registered

Nordic Nanovector ASA - share capital increase registered Oslo, Norway, 1 July 2020 Reference is made to the stock exchange notice by Nordic...

Jul 01, 2020, 01:54 ET Nordic Nanovector ASA: Allocation of Restricted Stock Unites (RSUs) to the Board of Directors

Reference is made to the minutes from Nordic Nanovector ASA's (the "Company") (OSE: NANO) annual general meeting held on 10 June 2020 in Oslo, Norway ...